Skip to main content

Table 2 Assessment of patients’ quality of life

From: Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life

 

Group A (n= 58)

Group B (n= 36)

P value

Functional scales, mean ± SD

   

Physical status

69.5 ± 31.3

67.8 ± 33.4

NS

Working ability

58.6 ± 40.1

55.4 ± 42.2

NS

Cognitive functioning

67.5 ± 34.8

66.1 ± 36.6

NS

Emotional functioning

62.3 ± 38.6

59.4 ± 28.5

NS

Social functioning

58.1 ± 32.5

53.3 ± 39.7

NS

Global quality of life

61.9 ± 33.3

51.7 ± 37.0

NS

Symptom scales, mean ± SD

   

Fatigue

48.9 ± 32.1

68.1 ± 36.3

P < 0.05

Nausea and vomiting

26.8 ± 20.4

53.7 ± 32.6

P < 0.05

Pain

36.2 ± 28.5

34.2 ± 30.9

NS

Dyspnea

22.0 ± 27.9

32.2 ± 22.8

NS

Insomnia

55.7 ± 38.7

61.1 ± 41.7

NS

Appetite loss

33.3 ± 36.1

43.3 ± 39.1

NS

Constipation

23.8 ± 31.8

26.4 ± 30.4

NS

Diarrhea

21.0 ± 22.6

53.9 ± 38.5

P < 0.05

Financial difficulties

52.3 ± 37.3

58.8 ± 40.4

NS

Pancreas-specific pain

44.4 ± 29.2

49.5 ± 36.6

NS

Diet restriction

42.5 ± 32.0

54.1 ± 37.8

NS

Jaundice and pruritus

12.7 ± 20.1

18.8 ± 19.9

NS

Steatorrhea

36.1 ± 30.4

39.1 ± 34.7

NS

Poor body image

38.3 ± 34.2

59.8 ± 35.0

NS

Sexual dysfunction

66.8 ± 35.8

75.3 ± 41.1

NS

Dissatisfaction with care

61.2 ± 37.7

65.6 ± 39.1

NS

Bloating

41.7 ± 31.5

49.7 ± 37.4

NS

Bad-tasting food

29.4 ± 36.9

37.4 ± 38.2

NS

Indigestion

30.7 ± 30.1

39.5 ± 28.6

NS

Flatulence

35.7 ± 31.5

38.0 ± 32.3

NS

Difficulty gaining weight

49.5 ± 34.4

67.7 ± 40.5

P < 0.05

Weakness

45.9 ± 32.8

56.6 ± 42.7

NS

Dry mouth

40.5 ± 38.0

49.1 ± 36.9

NS

Treatment side-effects

39.1 ± 30.5

46.2 ± 33.8

NS

Worry about future

57.8 ± 35.8

66.3 ± 27.6

NS

Difficulty planning

34.6 ± 33.7

46.8 ± 45.2

NS

  1. SD standard deviation; NS no significant difference.